ATP1A2 and triple-A syndrome: Our study reported that the ATP1A2 specifically expressed in VSMCs was significantly downregulated in AAA, which was confirmed to have the ability to regulate blood pressure in many previous studies, thus implying a potential therapeutic target for patients with hypertension and AAA.